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ABSTRACT
5-hydroxymethylcytosine is a new epigenetic modification deriving from 
the oxidation of 5-methylcytosine by the TET hydroxylase enzymes. DNA 
hydroxymethylation drives DNA demethylation events and is involved in the control 
of gene expression. Deregulation of TET enzymes causes developmental defects and 
is associated with pathological conditions such as cancer. Little information thus far is 
available on the regulation of TET activity by post-translational modifications. Here we 
show that TET1 protein is able to interact with PARP-1/ARTD1 enzyme and is target 
of both noncovalent and covalent PARylation. In particular, we have demonstrated 
that the noncovalent binding of ADP-ribose polymers with TET1 catalytic domain 
decreases TET1 hydroxylase activity while the covalent PARylation stimulates TET1 
enzyme. In addition, TET1 activates PARP-1/ARTD1 independently of DNA breaks. 
Collectively, our results highlight a complex interplay between PARylation and 
TET1 which may be helpful in coordinating the multiple biological roles played by 
5-hydroxymethylcytosine and TET proteins.
INTRODUCTION
Poly(ADP-ribosyl)ation (PARylation) is a post-
translational modification catalyzed by enzymes of the 
poly(ADP-ribose) polymerase (PARP) family, whose 
founding member is PARP-1 also known as ADP-
ribosyltransferase diphtheria toxin-like 1 (ARTD1) [1]. 
PARPs use NAD+ as substrate producing negatively 
charged polymers of ADP-ribose (PARs) which are then 
hydrolyzed by the poly(ADP-ribose) glycohydrolase 
(PARG) [2-4]. DNA damage highly stimulates the activity 
of PARP-1/ARTD1 [5, 6], which functions as DNA break 
sensor PARylating DNA damage response effectors [7-
10]. However, secondary DNA structures and allosteric 
trans-activating factors can also trigger PARylation [6, 11, 
12] supporting other housekeeping functions of PARP-1/
ARTD1 such as transcriptional regulation. 
Besides the covalent PARylation of target 
proteins, PARP-1/ARTD1 itself and other PARP family 
members typically undergo automodification reaction 
[3, 6]. Moreover, target proteins bringing specific PAR-
interacting motifs are able to accommodate PARs 
noncovalently [4, 13]. All these features of PARylation 
permit PARP-1/ARTD1 to modulate protein-protein 
interactions, subcellular localization or enzymatic 
activities [14-19]. Therefore, PARylation participates in 
a variety of cellular processes including DNA damage 
response, transcription and apoptosis [3, 16]. PARP-1/
ARTD1 regulates gene expression acting on histones [20, 
21], transcriptional factors (e.g. CTCF, SOX2) [22, 23] 
or proteins involved in chromatin dynamics (e.g. ISWI, 
HP1) [24, 25]. Furthermore, PARP-1/ARTD1 is able to 
directly influence epigenetic events [26] also through 
the modification of enzymes involved in histone post-
translational modifications (e.g. KDM5B, KDM4D) [17, 
27] or in the regulation of DNA methylation patterns (e.g. 
DNMT1, UHRF1) [19, 28]. 
As concerns DNA methylation, apart from inhibiting 
DNMT1 enzymatic activity by noncovalent PARylation 
[19], PARylated PARP-1/ARTD1 positively controls 
DNMT1 expression [29]. Recently, we have demonstrated 
that PARP activity is involved in the transcriptional 
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regulation of the Ten-eleven-translocation 1 (TET1) 
gene [30, 31] codifying for an enzyme that introduces 
the 5-hydroxymethylcytosine (5hmC), a new epigenetic 
modification present on DNA.
5hmC derives from the oxidation of 
5-methylcytosine (5mC) through the action of the 
2-oxoglutarate/Fe(II)-dependent DNA dioxygenases 
TET1, TET2 and TET3 [32]. 5hmC can function 
as an intermediate of both passive and active DNA 
demethylation processes [33, 34]. The action of 5hmC 
in passive DNA demethylation seems to depend on the 
reduced binding affinity of the maintenance methylase 
DNMT1 for 5hmC [35]. As concerns active DNA 
demethylation, the presence of 5hmC is a prerequisite for 
sequential oxidation reactions, and even they are catalyzed 
by TET enzymes leading to formation of 5-formylcytosine 
(5fC) and 5-carboxylcytosine (5caC) [36]. Thymine DNA 
glycosylase (TDG)-mediated base excision repair (BER) 
has a pivotal role in the removal of 5fC and 5caC and 
re-introduction of unmethylated cytosine [37]. However, 
5hmC is now considered as the sixth base of DNA 
introducing an additional epigenetic code onto genome 
[32, 38]. In mammals, the levels of 5hmC are different 
in tissues and cell types. Brain and embryonic stem cells 
show the highest abundance of DNA hydroxymethylation 
[39, 40]. 5hmC is depleted in stable heterochromatic 
regions, while it is frequently associated with promoter-
proximal regions, enhancers or transcription factor binding 
sites. Moreover, 5hmC is particularly enriched in CpG 
islands (CGIs) with low to medium GC-content but it is 
depleted in strong CGI which are generally completely 
unmethylated [41-44]. Genomic distribution of 5hmC 
mainly concentrated in proximity of coding sequences 
or of distal regulative elements supports the involvement 
of 5hmC in transcriptional regulation. Accordingly, a 
number of proteins display binding preference towards 
5hmC thus functioning as readers of this modification and 
interpreters of the 5hmC epigenetic code. Notably, specific 
binders of 5fC or 5caC have also been identified [45, 46] 
and recent evidence has suggested the involvement of 
these additional DNA modifications in the regulation of 
transcription influencing RNA polymerase II activity as 
well as DNA methylation dynamics on active promoters 
[47-49]. Besides a role of PARylation in preserving a 
permissive chromatin state on TET1 gene promoter [31, 
50], an involvement of PARs has also been demonstrated 
for the recruitment of TET1 protein onto specific loci 
during adipocyte differentiation [51]. Considering the 
multiple ways of action of PARylation in the regulation of 
protein functions [6, 16], we decided to investigate further 
the interplay between TET1 and PARP-1/ARTD1. All in 
all, our results highlighted that TET1 is a target of both 
covalent and noncovalent PARylation with consequences 
on TET enzymatic activity and that TET1 is in itself able 
to stimulate PARP-1/ARTD1 activation.
RESULTS
PARP inhibition affects TET1-mediated 5hmC 
formation
HEK293T cells were treated with two competitive 
inhibitors of PARP activity, Pj-34 and ABT-888. Both 
PARP inhibitors provoked the disappearance of PAR levels 
which was associated with a reduction of TET1 protein 
(Figure 1A). The transcriptional analysis of the main genes 
codifying for PARP machinery members (i.e. PARP-1, 
PARP-2, PARP-3 and PARG) showed no differences after 
PAR depletion (Supplementary Figure S1). Dot-blot and 
ELISA-based 5hmC quantification analyses evidenced 
that the inhibition of PARP activity caused a moderate 
reduction of the global content of 5hmC with respect to 
control cells (Figure 1B and Supplementary Figure S2A). 
The silencing of TET1 (Figure 1C) was performed to 
analyse the involvement of TET1 activity in the formation 
of 5hmC in HEK293T and its contribution to the effects 
mediated by PARP inhibition. 5hmC dot-blot analysis 
showed that silencing of TET1 markedly decreases the 
formation of 5hmC in HEK293T with respect to CTRL-
silenced cells. Notably, the effect of PARP inhibition on 
5hmC formation was no longer evident after the silencing 
of TET1 indicating that TET1 protein has a major role in 
this phenomenon in HEK293T cells (Figure 1D).
The action of PARylation on TET1 enzyme is not 
limited to protein recruitment
Engineered transcription activator-like effector 
(TALE) is customizable DNA-binding domain designed 
to target specific sites on genome [52]. We decided to use 
TALEs fused to TET1 protein [53] to obtain a recruitment 
of TET1 onto DNA independently of PARylation (Figure 
2A). In fact, the noncovalent PARylation of murine TET1 
has been described as being involved in the recruitment 
of this protein on specific loci during adipocyte 
differentiation [51]. Being TALE constructs fused to the 
human TET1 protein, we confirmed the conservation of 
putative PAR-binding motifs in it. Moreover, we identified 
an additional site for noncovalent PARylation in an 
aminoacid sequence of the human TET1 catalytic domain 
absent from the murine TET1 protein (Supplementary 
Figure S3). 
Blast analysis of two sequences recognized by two 
different TALE-TET1 full-length proteins (FL-1 and FL-2) 
showed that similar DNA regions are randomly distributed 
on genome (data not shown). According to this, a global 
increase of 5hmC levels was effectively evidenced after 
overexpression of FL-1 or FL-2 TALE-TET1 proteins 
(Figure 2B and Supplementary Figure S4A). Notably, 
treatment with the PARP inhibitor ABT-888 of HEK293T 
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Figure 1: Inhibition of PARP activity affects TET1-dependent 5hmC formation. A. Western blot analysis showing the effect 
of PARP inhibition on HEK293T cells treated with Pj-34 and ABT-888 for 72 hrs. B. 5hmC dot-blot analysis after inhibition of PARylation 
for 72 hrs and relative quantification. Results are shown as means ± S.E.M. (n = 5). C. Western blot analysis showing the silencing of TET1 
and the levels of PARs after ABT-888 treatment. D. 5hmC dot-blot analysis and relative quantification after inhibition of PARylation for 72 
hrs in control (siCTRL) and TET1-silenced (siTET1) cells. Results are shown as means ± S.E.M. (n = 4). Quantification of 5hmC levels was 
performed by densitometric analysis using methylene blue (MB) staining as DNA loading control. P-values were determined by ANOVA 
with post hoc Tukey’s test (*P < 0.05; **P < 0.01; ***P < 0.001).
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cells overexpressing TALE-TET1 FL induced new 
increase of 5hmC levels with respect to untreated cells 
(Figure 2C and Supplementary Figure S2B). These results 
highlight the existence of additional roles played by 
PARylation on 5hmC formation, which are independent 
of TET1 recruitment on genome. To investigate a possible 
regulation of TET activity mediated by PARylation, two 
different TALE proteins fused only to TET1 catalytic 
domain (CD-1 and CD-2) were overexpressed (Figure 2D 
and Supplementary Figure S4B). Also TALE-TET1 CD 
overexpression caused a global increase of 5hmC (Figure 
2E), which even in this case was more evident after the 
inhibition of PARP activity (Figure 2F and Supplementary 
Figure S2C). 
TET1 is a protein partner of PARP-1/ARTD1
A possible direct influence of PARylation on TET1 
activity would imply an interaction between PARP-1 
and TET1 proteins. Therefore, co-immunoprecipitation 
experiments were performed by using anti TET1 or anti 
PARP-1 antibodies demonstrating the binding between 
these proteins. Notably, after treatment with the PARP 
inhibitor ABT-888, the binding between TET1 and PARP-
1 was partially affected suggesting that it is stabilized by 
PARs (Figure 3A). 
Further demonstration of the interaction between 
TET1 and PARP-1 was obtained through GST pull-down 
experiments by using a GST-tag fused to the catalytic 
domain of TET1 (GST-TET1) presenting the PAR-
Figure 2: The levels of 5hmC, deriving from TALE-TET1 protein overexpression, increase after PARP inhibition. A. 
Schematic illustrating the TALE fused to TET1 full-length protein (TET1 FL) containing the CXXC-type zinc-binding domain (CXXC), the 
cysteine-rich region (Cys-rich), the catalytic domain (CD) and the PAR-binding motifs. B. Dot-blot analysis of 5hmC after overexpression 
of two different TALE-TET1 FL (FL-1 and FL-2) proteins for 72 hrs. Results are shown as means ± S.E.M. (n = 3) C. Dot-blot analysis of 
5hmC after overexpression of FL-1 and FL-2 and inhibition of PARP activity. Results are shown as means ± S.E.M. (n = 3). D. Schematic 
illustrating the TALE fused to the catalytic domain of TET1 protein (TET1 CD) containing the cysteine-rich region (Cys-rich), the catalytic 
domain (CD) and the PAR-binding motifs. E. Dot-blot analysis of 5hmC after overexpression of two different TALE-TET1 CD (CD-1 
and CD-2) proteins for 48 hrs. Results are shown as means ± S.E.M. (n = 3). F. Dot-blot analysis of 5hmC after overexpression of CD-1 
and CD-2 and inhibition of PARP activity. Results are shown as means ± S.E.M. (n = 3). Quantification of 5hmC levels was performed by 
densitometric analysis using methylene blue (MB) staining as DNA loading control. P-values were determined by ANOVA with post hoc 
Tukey’s test or paired Student t-test (*P < 0.05; **P < 0.01; ***P < 0.001).
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binding motif typical of the human protein. Incubation 
of GST-TET1 with HEK293T nuclear extracts evidenced 
that endogenous PARP-1 is able to bind the C-terminal 
catalytic domain of TET1 (Figure 3B). GST pull-down 
was also performed in presence of recombinant PARP-
1 indicating that the binding to TET1 is actually direct 
(Figure 3C).
TET1 protein binds PARs noncovalently
Immunoprecipitation experiments were performed 
with anti PAR antibodies confirming that endogenous 
TET1 is a target of PARylation (Figure 4A). In vitro PAR-
binding assays with either free PARs or PARP-1 attached 
PARs were performed to demonstrate that TET1 catalytic 
domain is able to bind PARs noncovalently. PAR blot 
assay was carried out spotting 3-fold serial dilution of 
GST-TET1, histone H2B as positive control and GST-tag 
as negative control. Incubation with free PARs followed 
by anti PAR immunoblotting demonstrated the capacity 
of TET1 for binding PARs noncovalently. Notably, the 
interaction between PARs and TET1 catalytic domain 
persists even in presence of an excess of competitor 
double-stranded DNA (dsDNA) used to rule out non-
specific interactions due to the highly negatively charged 
nature of PARs (Figure 4B). GST pull-down experiments 
performed by using in vitro automodified PARP-1 
demonstrated that TET1 is able to bind PARs even when 
they are present on PARP-1 protein (Figure 4C). 
Inhibitory effect of noncovalent PARylation on 
TET1 activity
To verify whether PARylation is effectively able 
to influence TET1 hydroxylase activity, HEK293T cells 
were treated with the PARP inhibitors Pj-34 and ABT-
888 (Supplementary Figure S5) and TET activity was 
measured in vitro. An increase of total TET activity was 
Figure 3: TET1 interacts with PARP-1 protein also in absence of PARs. A. Co-Immunoprecipitation experiments performed 
with anti TET1 or anti PARP-1 antibodies on nuclear lysates of HEK293T treated or not with ABT-888 for 6 hrs. Input lysate was 10% of 
total. B. GST pull-down performed by using GST-TET1 and GST as control in presence of HEK293T nuclear lysates or C. recombinant 
PARP-1 protein.
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evidenced in absence of PARylation thus suggesting an 
inhibitory role of PARs on TET enzymes (Figure 5A).
To test the effect of noncovalent PARylation on 
TET1 enzymatic activity, GST-TET1 was incubated 
with PARs synthetized in vitro and purified. Notably, a 
reduction of TET1 hydroxylase activity was observed 
in presence of PARs suggesting that the noncovalent 
PARylation of TET1 catalytic domain is able to inhibit 
TET1 activity (Figure 5B). 
TET1 is covalently PARylated
Besides noncovalent PARylation, proteins can 
also be covalently modified by PARs. To test whether 
TET1 can also be a target of covalent PARylation, an in 
vitro PARP assay was performed incubating GST-TET1 
with recombinant PARP-1, NAD+ and nicked DNA to 
induce PARP activation. Western blot analysis with 
anti PAR antibodies evidenced time-dependent smears 
corresponding to PARP-1 activation. Moreover, the anti 
PAR antibody also revealed bands coincident with GST-
TET1 molecular weight (arrow) indicating that TET1 
is covalently PARylated in vitro. Notably, GST-TET1 
sample incubated for 20 min with PARP-1 showed a more 
intense high molecular weight smear obtained with anti 
PAR antibody than the corresponding GST control sample 
suggesting that TET1 protein may have in itself the 
capacity for stimulating PARP activity (Figure 6A). Based 
on this, additional experiments were performed incubating 
GST-TET1 or GST alone with PARP-1 but in absence 
of activating nicked DNA. The incubation of PARP-1 
Figure 4: TET1 interacts noncovalently with PARs. A. Immunoprecipitation experiments performed with anti PAR antibody on 
HEK293T nuclear lysates. Input lysate was 10% of total. B. PAR blot assay of GST-TET1, GST alone (negative control) and histone H2B 
(positive control) incubated with free PARs with/without dsDNA as competitor. C. GST pull-down performed by using GST-TET1 and 
GST as control in presence of automodified PARP-1 protein. 
Figure 5: TET1 activity is negatively influenced by noncovalent PARylation. A. 5mC-hydroxylase TET activity measured 
in nuclear extracts of HEK293T treated or not with PARP inhibitors for 6 hrs. Results are shown as means ± S.E.M. (n = 3). B. 5mC-
hydroxylase TET activity of recombinant GST-TET1 enzyme measured in presence/absence of PARs. Results are shown as means ± S.E.M. 
(n = 5). P-values were determined by ANOVA with post hoc Tukey’s test or paired Student t-test (*P < 0.05).
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with GST-TET1 for different times (Figure 6B) or with 
different concentrations of GST-TET1 (Figure 6C) showed 
a time- and dose-dependent increase of anti PAR signal, 
respectively. These results allowed the demonstration 
that TET1 is effectively able to activate PARP-1 
independently of DNA damage. Notably, the presence 
of bands coincident with GST-TET1 molecular weight 
(arrow) detectable with anti PAR antibodies indicated that 
following the stimulation of PARylation by TET1, PARP-1 
is in turn able to covalently modify TET1 protein (Figure 
6B and 6C). The possibility that the covalent modification 
of TET1 may modulate the activity of TET1 protein was 
tested purifying PARylated GST-TET1 and measuring its 
hydroxylase activity in vitro. This assay suggested that the 
covalent PARylation of TET1 stimulates TET enzymatic 
activity (Figure 6D).
DISCUSSION
The complexity of events involving 5hmC and its 
derivatives implies a fine-tuned regulation of TET protein 
activities to coordinate their actions [54]. Post-translational 
Figure 6: TET1 is covalently PARylated and is able to activate PARP-1. A. In vitro PARylation assay performed incubating 
PARP-1 with GST-TET1 for different times or with GST alone (negative control), in presence of nicked DNA added to stimulate PARP 
activity. B. In vitro PARylation assay in absence of nicked DNA performed by using PARP-1 with GST-TET1 or with GST alone (negative 
control) for different times or C. at different concentrations. D. 5mC-hydroxylase TET activity of GST-TET1 covalently modified by 
PARP-1. Results are shown as means ± S.E.M. (n = 4). P-values were determined by ANOVA with post hoc Tukey’s test (*P < 0.05, **P < 
0.01). Arrows indicate the bands revealed by anti PAR antibodies and corresponding to GST-TET1 molecular weight.
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modifications are typically known to expand the range of 
functions of protein influencing subcellular localization, 
protein-protein or protein-nucleic acid interactions as well 
as enzymatic activities. The most studied modification of 
TETs is certainly the O-linked glycosylation catalysed 
by the O-linked N-acetylglucosamine (O-GlcNAc) 
transferase (OGT), which is able to modify all TET 
proteins but with different functional outcomes [55]. For 
example, while TET1 glycosylation seems to enhance 
protein stability [56], TET3 glycosylation regulates the 
subcellular localization [57]. Glycosylation of TETs 
also affects their phosphorylation which has recently 
been identified on TET proteins but whose function is 
still unknown [58]. In parallel, TET proteins are able to 
influence OGT activity with consequences on histone 
modifications and transcription [59].
An interesting link has also been observed between 
TET enzymes and PARylation [31, 51, 60]. TET1 is able 
to bind PARs noncovalently as it brings a PAR-binding 
motif within the N-terminal domain and another two 
motifs adjacent to the catalytic domain. The noncovalent 
PARylation of TET1 was demonstrated to be involved in 
the recruitment of TET1 onto specific loci by a PARylated 
protein complex comprising also PPARγ, which is the 
key regulatory factor in adipogenesis [51]. In addition, 
we have recently demonstrated a transcriptional control 
of TET1 gene mediated by PARylation [31], result also 
confirmed by another group [50]. The well-known ability 
of PARP-1/ARTD1 to regulate protein functions by 
several modes [6, 16] prompted us to investigate further 
the interplay between PARylation and 5hmC formation 
focusing on TET1 enzymatic activity. 
The use of TALE-TET1 fusion proteins (TET1 
full-length or catalytic domain) highlighted new roles 
played by PARylation on TET1 function independently 
of protein recruitment which now is mediated by TALEs. 
Their overexpression induced an increase of 5hmC levels 
which was even more evident in presence of PARP 
Figure 7: Model summarizing the possible outcomes of covalent and noncovalent PARylation of TET1 on its biological 
functions. TET1 can stimulate the activity of PARP-1 independently of DNA damage. In turn, TET1 can be PARylated by PARP-1 both 
noncovalently and covalently with consequences on TET1 activity. PARylation of TET1 may regulate the hydroxylase activity during 
the different steps of the DNA demethylation processes. Apart from the regulation of TET activity, PARylation of TET1 may act in the 
assemblage of complexes containing PAR-interacting proteins involved in the regulation of DNA demethylation and transcription.
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inhibitors. The increase of 5hmC formation cannot be 
justified by the involvement of PARylation in the control 
of TET1 expression or recruitment onto genome. Rather, 
this finding suggests that PARs could suppress TET1 
enzymatic activity as also indicated by the use of TALE 
constructs fused to the sole catalytic domain of TET1. 
Notably, TALE-TET1CD possesses PAR-binding motifs 
which interacting noncovalently with PARs may inhibit 
TET hydroxylase activity. The hypothesis of an inhibitory 
effect of PARs on TET enzymatic activity was validated 
measuring the total TET activity in cells after inhibition 
of PARylation. In addition, after the confirmation of 
a strong noncovalent interaction between PARs and 
TET1, the incubation of recombinant TET1 catalytic 
domain with PARs synthesised in vitro indicated that 
noncovalent PARylation of TET1 is effectively involved 
in the enzymatic repression. Further co-IP and pull-down 
experiments demonstrated an interaction between TET1 
and PARP-1/ARTD1 which seems to be strengthened 
by PARs even though the proteins can also interact 
independently. 
The identification of in vitro inhibitory action of 
noncovalent PARylation on TET1 enzyme is apparently in 
disagreement with the reduction of 5hmC levels observed 
after treatment of HEK293T cells with PARP inhibitors. 
Such in vivo effect of PAR depletion on genomic DNA is 
most likely to be the net result which also depends on the 
decrease of TET1 expression as well as on the failure of 
TET1 recruitment onto DNA mediated by PARs. 
PARP-1/ARTD1 can modify target proteins 
covalently on glutamate, aspartate or lysine residues 
[61] and some proteins can undergo both covalent 
and noncovalent PARylation [10, 15, 22, 62]. In vitro 
experiments showed that TET1 can indeed be covalently 
modified by PARP-1/ARTD1 and this modification seems 
to have a different outcome on TET1 activity resulting in 
a stimulation of the enzyme. Notably, TET1 and PARP-
1/ARTD1 are also connected by the ability of TET1 to 
trigger PARylation in vitro in absence of activating nicked 
DNA. In this context, the covalent modification of TET1 
has also been evidenced.
Collectively, these results enlarge the complexity 
of the cross-talk existing between TET1 and PARP-1/
ARTD1. In fact, apart from the involvement of PARylation 
in the transcriptional regulation of TET1 gene [31, 50] 
and recruitment of TET1 protein onto specific loci [51], 
our findings highlight for the first time a direct control 
of PARs over TET1 hydroxylase activity. In particular, a 
bimodal influence of noncovalent and covalent PARylation 
emerges on the regulation of TET1 enzymatic activity. 
These multiple connections between PARP-1/ARTD1 
and TET1 are not surprising considering the different 
ways adopted by PARylation in the regulation of protein 
functions [6, 16] and above all the numerous roles played 
by TET1 in the regulation of epigenetic dynamics [54]. 
Accordingly, 5hmC can be an intermediate of 
both active and passive DNA demethylation [33, 34]. 
In particular, TET enzyme activity is not limited to the 
formation of 5hmC but it is also responsible for the 
transformation of 5hmC in its derivatives, 5fC and 5caC, 
during the active DNA demethylation process [36, 37]. 
Besides the well-known involvement of PARP-1/ARTD1 
in the BER pathway [3] which leads the reintroduction of 
unmethylated cytosines, a contribution of PARylation in 
the control of the sequential transformations of 5mC into 
5hmC, 5fC or 5caC mediated by TETs can be suggested. 
Moreover, during active DNA demethylation the 
PARylation of TET1 itself could favour the assemblage 
of those DNA repair effectors known to be recruited on 
damaged DNA by PAR noncovalent interaction [8, 9, 13]. 
It is noteworthy that TET1 is involved in 
transcriptional regulation even independently of its 
hydroxylase activity. This is also supported by the 
evidence that TET1, by its CXXC domain, preferentially 
binds to unmehylated CGIs where the hydroxylase activity 
is not required missing the 5mC substrate [63-65]. In 
this context, PARylated TET1 could limit the access of 
DNMT1 onto DNA preventing DNA methylation [19, 29, 
64] and it can favour the binding of transcription factors 
that bind PARs noncovalently (Figure 7). 
In conclusion, in this work we have identified for the 
first time a mechanism involved in the direct regulation of 
TET enzymatic activity mediated by PARylation. A deeper 
characterization of the interplay between TET1 and PARP-
1/ARTD1 also in relation with other post-translational 
modifications would highlight new mechanisms driving 
TET1 functions. This is relevant if considering that TET 
enzymes and 5hmC are not only involved in development 
and cell differentiation [34] but also in several pathological 
conditions including cancer [66-68] and neurodegenerative 
disorders [69-71].
MATERIALS AND METHODS
Cell culture, treatment and transfection
HEK293T cells were grown in high glucose 
DMEM (Sigma-Aldrich) containing 10% FBS (Sigma-
Aldrich), 2 mM L-glutamine (Sigma-Aldrich) and 50 U/
ml Penicillin–Streptomycin (Sigma-Aldrich). Treatments 
of cells were performed replacing medium every 24 hrs 
with the PARP inhibitors PJ-34 (Sigma-Aldrich, final 
concentration 1 μM), and ABT-888 (Enzo Life Sciences, 
final concentration 1 μM). Transfection of HEK293T cells 
was performed by using Lipofectamine 2000 reagent 
(Life Technologies) adopting the manufacturer’s protocol. 
TET1 silencing was obtained by using DsiRNA Duplex 
for TET1 gene (IDT Integrated DNA technologies, final 
concentration 10nM). TALE-TET1 overexpression 
plasmids namely JA740 (Addgene plasmid # 49939), 
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SL357 (Addgene plasmid # 49936), MLM3713 (Addgene 
plasmid # 49946), MLM3727 (Addgene plasmid # 49961) 
were a gift from Keith Joung. In the manuscript, JA740, 
SL357, MLM3713, MLM3727 plasmids correspond to 
FL-1, FL-2, CD-1, CD-2. 
Antibodies
The following monoclonal antibodies were used: 
PARP-1 (clone C2-10; Enzo Life Sciences), PAR (clone 
10HA; Trevigen), TET1 (Genetex), Myc-tag (9E10 
clone, hybridoma-conditioned medium), GST (Thermo), 
αTUB (Sigma-Aldrich), FLAG (Thermo Scientific Pierce 
Antibodies). The following polyclonal antibodies were 
used: PARP-1 (Enzo Life Sciences), PAR (10H, kind gift 
of A. Burkle), 5hmC (Active motif), Lamin B1 (Abcam).
Western blot analysis
Total cell lysates were prepared in RIPA buffer 
(50 mM Tris-HCl at pH 7.4, 150 mM NaCl, 1% NP-40, 
0.5% sodium deoxycholate, 0.1% SDS and 1 mM EDTA) 
and normalized for protein concentration. Nuclei were 
obtained after incubation of cells for 15 min in ice with 
isolation buffer (10 mM Tris-HCl at pH 7.8, 4 mM MgCl
2
 
, 1 mM EDTA, 0.5 mM DTT, 1% Triton X-100, 0.25 
M Sucrose); pelleted nuclei were washed with isolation 
buffer without Triton X-100 and centrifuged. Each 
buffer was supplemented with protease inhibitor cocktail 
(Complete EDTA-free, Roche Applied Science). Protein 
extracts were resolved by SDS-PAGE in 6% acrylamide/
bis-acrylamide gels, transferred onto Hybond-ECL 
nitrocellulose membranes (Amersham Biosciences) and 
probed with the indicated antibodies. 
Dot blot assay
DNA was extracted with DNeasy Blood & Tissue 
Kit (QIAGEN), denatured in 0.4 M NaOH, 10mM EDTA 
at 95°C for 10 min and then neutralized by adding an 
equal volume of cold 4 M ammonium acetate (pH 7.0). 
2-fold dilutions of denatured DNA samples were spotted 
on nitrocellulose membrane Hybond-N+ (Amersham 
Biosciences) in an assembled Bio-Dot apparatus (Bio-Rad 
Laboratories). Vacuum was subsequently applied to filter. 
Blotted membrane was washed with 2X SSC buffer and 
air-dried. The membrane was then blocked with 5% non-
fat milk and incubated with anti 5hmC antibody (Active 
motif). Binding of an HRP-conjugated secondary antibody 
was visualized by chemiluminescence (Amersham ECL 
Western Blotting detection reagents). To control equal 
spotting of total DNA onto the membrane, the same 
blotted filter was then stained with 0.02% methylene blue 
in 0.3 M sodium acetate (pH 5.2). A total of 3.5 µg of 
DNA was used for samples deriving from untransfected 
HEK293T cells, 1.75 µg of DNA from TALE-TET1 
FL samples and 350 ng of DNA from TALE-TET1 CD 
samples. Densitometric analysis was performed by 
Quantity One Software (Bio-Rad Laboratories) according 
to manufacturer’s instructions.
ELISA-based quantification of 5hmC
Colorimetric quantification of 5hmC was performed 
by using the Quest 5-hmC™ DNA ELISA Kit (Zymo 
research) according to manufacturer’s instructions. 
RNA extraction and quantitative RT-PCR
Total RNA was isolated from cells by using 
RNeasy mini kit (Qiagen) following the manufacturer’s 
instructions. RNase-free DNase (Qiagen) treatment was 
performed to eliminate contaminating DNA. Total RNA 
was subjected to reverse transcription using SuperScript 
VILO cDNA Synthesis Kit (Life Technologies). 
Transcriptional analysis was performed by quantitative 
RT-PCR (qRT-PCR) using iCycler IQ detection system 
(Bio-Rad). For quantitative PCR reactions, Taqman 
Gene Expression Assays (PARP-1 Hs00242302_m1; 
PARP-2 Hs00193931_m1; PARP-3 Hs00193946_m1; 
PARG Hs00608254_m1; GUSB Hs99999908_m1) and 
EXPRESS qPCR Supermix Universal (Life Technologies) 
were used. Measurement of gene expression was 
performed using the comparative cycle threshold method. 
Co-immunoprecipitation
Nuclei isolated from HEK293T cells were lysed in 
Co-IP buffer (50 mM Tris-HCl pH 7.4, 250 mM NaCl, 
0.5% NP-40 and 2% glycerol) supplemented with protease 
inhibitors (Complete EDTA-free, Roche Applied Science). 
NaCl and glycerol concentrations were adjusted to 150 
mM and 1%, respectively. Lysates were then pre-cleared 
with Protein G-agarose beads or Protein A-agarose beads 
(Millipore) on a rotating shaker at 4°C for 2.5 hrs. Pre-
cleared lysates were incubated with specific antibodies or 
relative normal control IgGs (Santa Cruz Biotechnology) 
on a rotating shaker overnight at 4°C. Agarose beads, 
previously saturated with BSA (1 μg/μl) overnight, were 
added to the lysate/antibody solutions and incubated for 3 
hrs on a rotating shaker at 4°C. Subsequently, beads were 
washed 10 times in Co-IP wash buffer (50 mM Tris-HCl 
pH 7.4, 150 mM NaCl, 0.5% NP-40 and 1% glycerol), 
proteins were eluted boiling in 2X Laemmli buffer and 
then analysed by Western blotting.
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GST pull-down
5 pmol of recombinant GST-TET1 or recombinant 
GST-tag (SignalChem) were incubated with 25 µl of PBS-
washed Glutathione Sepharose 4B (GE Healthcare) for 1 
hr in rotation at 4°C. After washing with equilibration 
buffer (50 mM Tris-HCl pH 8.0, 5 mM MgCl
2
), 5 pmol 
of unmodified recombinant PARP-1 (Enzo Life Sciences) 
or automodified recombinant PARP-1 were added to 
equilibration buffer and incubated with GST-TET1 or GST 
for 2 hrs in rotation at 4°C. Samples were washed 10 times 
with wash buffer (50 mM Tris-HCl pH 8.0, 5 mM MgCl
2
, 
150 mM NaCl, 0.1% NP-40, 1% glycerol) and elution was 
obtained boiling with one volume of 2X Laemmli sample 
buffer. PARP-1 automodification was obtained incubating 
5 pmol of recombinant PARP-1 in PARP activity buffer 
(50 mM Tris-HCl pH 8.0, 5 mM MgCl
2
, 0.2 mM DTT, 3 
µM NAD+) in presence of 200 ng of DNAse I activated 
DNA (Enzo Life Sciences) for 45 min at 25°C. GST pull-
down was also performed in presence of 300 µg of nuclear 
proteins with an incubation of 4 hrs in rotation at 4°C.
Synthesis and purification of PARs
Purification of PARs was performed as previously 
described [62]. Briefly, 1.5 units of human recombinant 
PARP-1 (Enzo Life Sciences) were incubated for 2 hrs at 
30°C in poly(ADP-ribosyl)ation buffer (100 mM Tris-HCl 
pH 8.0, 10 mM MgCl
2
, 20 mM DTT, 200 µM NAD+, 10% 
ethanol, 10% glycerol) with 500 ng of nicked DNA (Enzo 
Life Sciences). Reaction was stopped with 3 M sodium 
acetate (pH 5.2) and 0.7 volume of isopropanol and kept 
overnight at -20°C. Samples were then centrifuged for 
30 min at 16000 x g and washed with 70% ethanol. The 
pellet was resuspended in 10 mM Tris-HCl (pH 8.0), 1 
mM EDTA and 200 µg of proteinase K (Sigma-Aldrich) 
and incubated overnight at 37°C. Then, 1 volume of 1 
M KOH/100 mM EDTA was added and the samples 
were incubated for 2 hrs at 37°C, centrifuged and PARs 
were recovered by chloroform/isoamyl alcohol/ethanol 
precipitation. Pellets were resuspended in RNase DNase-
free water (Millipore).
PAR blot assay
Recombinant proteins in equal molar amounts were 
dotted onto nitrocellulose membranes (Hybond ECL 
Amersham Pharmacia Biotech) in an assembled Bio-Dot 
apparatus (Bio-Rad). The blots were treated as described 
previously [62]. Briefly, blots were incubated in TBS-T 
(TBS-0.05% Tween 20) containing PARs with or without 
dsDNA (double-stranded DNA) of salmon sperm as 
competitor, at a PAR:dsDNA ratio of 1:25 (w/w). After 
incubation for 3 hrs at 21°C, membranes were extensively 
washed with TBS-T and subjected to immunoblotting 
using mouse monoclonal anti PAR antibody (10 HA, 
Trevigen) and goat anti-mouse horseradish peroxidase 
conjugated antibody (Santa Cruz Biotechnology). 
Recombinant H2B (histone 2B, Sigma–Aldrich) was used 
as positive control while GST as the negative one.
In vitro TET enzymatic activity analysis
TET enzymatic activity was measured by using 
the ELISA-based Epigenase 5mC Hydroxylase TET 
Activity/Inhibition Assay Kit (Epigentek) according to 
manufacturer’s instructions. Incubation time of TET1 
recombinant enzyme/nuclear lysates was extended to two 
hrs.
In vitro PARylation assay
7 pmol of GST-TET1 (SignalChem) or recombinant 
GST-tag were incubated with 25 µl of PBS-washed 
Glutathione Sepharose 4B (GE Healthcare) for 1 hr in 
rotation at 4°C. After washing with equilibration buffer 
(50 mM Tris-HCl pH 8.0, 5 mM MgCl
2
), 3.5 pmol of 
recombinant PARP-1 (Enzo Life Sciences) were added 
to PARP activity buffer (50 mM Tris-HCl pH 8.0, 5 mM 
MgCl
2
, 0.2 mM DTT, 3 µM NAD
+) in presence of DNAse 
I activated DNA (Enzo Life Sciences) and incubated with 
GST-TET1 or GST at 25°C for different time. Reaction 
was stopped adding one volume of 2X Laemmli sample 
buffer. For in vitro TET activity of covalently PARylated 
GST-TET1, elution was performed in 50 mM Tris-HCl 
pH 8.0 and 20 mM reduced glutathione after extensive 
incubations with detergent containing buffer (50 mM Tris-
HCl pH 8.0, 5 mM MgCl
2
, 200 mM NaCl, 0.1% NP-40, 
1% glycerol) to wash out PARP-1 protein. Experiments 
were also performed without DNAse I activated DNA 
incubating 1 pmol of GST-TET1 or GST in presence of 
0.4 pmol of PARP-1 for different time or incubating 9, 1.8, 
2.7, 3.6 pmol of GST-TET1 or GST in presence of 9 pmol 
of PARP-1 for 15 min at 25°C. 
Statistics
Values are expressed as mean ± SEM. Paired 
Student t-test or ANOVA with post hoc Tukey’s test 
were used to compare results between different groups. 
Significance was accepted at the level of P < 0.05.
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